Actelion Acquires Option to Buy CNS Drug Developer Trophos

By Heather Cartwright

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 8 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1363     ISSN: 1756-7874

Section: Mergers & Acquisitions



Actelion, the Swiss maker of the blockbuster pulmonary arterial hypertension drug Tracleer® (bosentan), has entered into an option agreement to acquire Trophos, based on the success of its Phase III candidate to treat amyotrophic lateral sclerosis...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details